Actuate Therapeutics, Inc. Common stock (ACTU) Fair Value 2026

ACTU · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-28, Actuate Therapeutics, Inc. Common stock (ACTU) trades at $1.66. QOC: 4.1/10. Value Trap Risk: 27/100 (LOW). 0/13 models active.

Key Facts

Ticker
ACTU
Price
$1.66
Quality Score
4.1/10
Value Trap Risk
27/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.1/10 signals weak fundamentals

What Fair Value Does Each Model Give ACTU?

0 Intrinsic Value Models vs. Current Price ($1.66)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Actuate Therapeutics, Inc. Common stock (ACTU) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Actuate Therapeutics, Inc. Common stock currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ACTU?

0 of 13 models are currently active for ACTU. See which stocks rank higher →

How Does ACTU Rank in Biotechnology?

Among 625 Biotechnology stocks, ACTU ranks #524 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Actuate Therapeutics, Inc. Common stock operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating ACTU should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ACTU a Value Trap?

CirclFi's Value Trap algorithm assigns ACTU a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Actuate Therapeutics, Inc. Common stock. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Actuate Therapeutics, Inc. Common stock's fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ACTU valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Actuate Therapeutics, Inc. Common stock Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MTVAMetaVia Inc.QOC 4.1TENXTenax Therapeutics, Inc.QOC 4.1XRTXXORTX Therapeutics Inc.QOC 4.1QNRXQuoin Pharmaceuticals, Ltd.QOC 4.1GRIGRI Bio, Inc.QOC 4.1NGENNervGen Pharma Corp.QOC 4.1LCTXLineage Cell Therapeutics, Inc.QOC 6.9ADXNAddex Therapeutics LtdQOC 5.5INTSIntensity Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MTVA · TENX · XRTX · QNRX · GRI · NGEN · LCTX · ADXN · INTS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ACTU?

6 companies across all industries closest to ACTU’s Quality of Company score of 4.1/10.

CRCWThe Crypto CompanyQOC 4.1PTPIPetros Pharmaceuticals, Inc.QOC 4.1VIPZVIP Play, Inc.QOC 4.1VGESVanguard Green Investment LimitedQOC 4.1TRXAT-REX Acquisition Corp.QOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CRCW · PTPI · VIPZ · VGES · TRXA · NVDA

Where Does ACTU Sit in CirclFi's Biotechnology Rankings?

ACTU is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Actuate Therapeutics, Inc. Common stock’s Valuation?

What is Actuate Therapeutics, Inc. Common stock's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Actuate Therapeutics, Inc. Common stock (ACTU). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ACTU overvalued or undervalued right now?

At $1.66, 0 of 0 active models suggest ACTU may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Actuate Therapeutics, Inc. Common stock's business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for ACTU?

Actuate Therapeutics, Inc. Common stock's QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ACTU?

CirclFi analyzes ACTU with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ACTU a value trap in 2026?

Actuate Therapeutics, Inc. Common stock's Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Actuate Therapeutics, Inc. Common stock (ACTU) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ACTU/ · Methodology
Primary sources for this ACTU valuation

Market data for ACTU as of ; valuations recomputed .